Canadá - inglés - Health Canada

angita pharma inc. - quetiapine (quetiapine fumarate) - tablet (extended-release) - 150mg - quetiapine (quetiapine fumarate) 150mg - atypical antipsychotics

Canadá - inglés - Health Canada

angita pharma inc. - quetiapine (quetiapine fumarate) - tablet (extended-release) - 200mg - quetiapine (quetiapine fumarate) 200mg - atypical antipsychotics

Canadá - inglés - Health Canada

angita pharma inc. - quetiapine (quetiapine fumarate) - tablet (extended-release) - 300mg - quetiapine (quetiapine fumarate) 300mg - atypical antipsychotics

Canadá - inglés - Health Canada

angita pharma inc. - quetiapine (quetiapine fumarate) - tablet (extended-release) - 400mg - quetiapine (quetiapine fumarate) 400mg - atypical antipsychotics

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 230.244 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate type a; calcium hydrogen phosphate dihydrate; purified talc; povidone; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 115.122 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; purified talc; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; povidone; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 172.683 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; magnesium stearate; microcrystalline cellulose; purified talc; colloidal anhydrous silica; sodium starch glycollate type a; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 115.122 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; lactose monohydrate; sodium starch glycollate type a; purified talc; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 345.366 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 400; calcium hydrogen phosphate dihydrate; povidone; hypromellose; colloidal anhydrous silica; titanium dioxide; magnesium stearate; purified talc; sodium starch glycollate type a; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; magnesium stearate; povidone; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; purified talc; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia